|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Supplemental Table 1. Characteristics of the non-, 2-h, and prolonged PMX-HP groups | | | | |
|  | Non-PMX group  (n = 76) | 2-h PMX group  (n = 22) | Prolonged PMX group  (n = 14) |  | |
| Age (years) | 68.9 ± 14.3 | 73.8 ± 14.0 | 74.8 ± 8.6 |  | |
| Male sex | 49 (64.5) | 13 (59.1) | 7 (50.0) |  | |
| APACHE II score † | 26.5 (20–31.8) | 24.5 (19–29.3) | 22.5 (18–29.5) |  | |
| Lactate (mmol/L) | 4.6 (3.4–7.3) | 5.1 (3.8–8.3) | 3.8 (2.8–5.5) |  | |
| Treatment using dexmedetomidine | 42 (55.3) | 13 (59.1) | 6 (42.9) |  | |
| Day 1 SOFA score ‡ | 10 (8–12) | 10.5 (8–12) | 11 (7–11.5) |  | |
| Day 1 C-reactive protein (mg/dL) | 14 (6.1–25.6) | 6.5 (2.2–21.4) | 17.5 (2.2–31.9) |  | |
| Day 1 procalcitonin (ng/mL) | 19.1 (3.5–92.6) | 44.9 (28.8–97.5) | 45.4 (22.2–154.0) |  | |
| Duration of PMX-HP per session (h) | - | 2.0 (2.0–2.0) | 5.5 (3.75–12.5) |  | |
| PMX-HP on the second day | - | 14 (63.6) | 3 (21.4) |  | |
| Renal replacement therapy | 29 (38.2) | 11 (50) | 10 (71.4) |  | |
| Site of infection  　Abdomen  　Thorax  　Others | 29 (38.2)  26 (34.2)  21 (27.6) | 14 (63.6)  2 (9.1)  6 (27.3) | 9 (64.3)  1 (7.1)  4 (28.6) |  | |
| Vasopressors  Noradrenalin  Vasopressin | 71 (93.4)  10 (13.2) | 22 (100)  5 (22.7) | 14 (100)  5 (35.7) |  | |
| Steroids | 52 (68.4) | 19 (86.4) | 11 (78.6) |  | |

Data are reported as mean ± standard deviation, median (interquartile range), or number (%). APACHE II: Acute Physiology and Chronic Health Evaluation II, SOFA: Sequential Organ Failure Assessment, PMX-HP: hemoperfusion with polymyxin B-immobilized fiber column

† The APACHE II score ranges from 0 to 71, with higher scores indicating more severe disease.

‡The SOFA score ranges from 0 to 24, with higher scores indicating more severe disease.